Logo image of CHRS

COHERUS BIOSCIENCES INC (CHRS) Stock Fundamental Analysis

NASDAQ:CHRS - Nasdaq - US19249H1032 - Common Stock - Currency: USD

1.07  -0.03 (-2.73%)

After market: 1.09 +0.02 (+1.87%)

Fundamental Rating

2

CHRS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. CHRS has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, CHRS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

CHRS had negative earnings in the past year.
In the past year CHRS has reported a negative cash flow from operations.
In multiple years CHRS reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: CHRS reported negative operating cash flow in multiple years.
CHRS Yearly Net Income VS EBIT VS OCF VS FCFCHRS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M -200M

1.2 Ratios

CHRS has a better Return On Assets (-0.09%) than 92.36% of its industry peers.
Industry RankSector Rank
ROA -0.09%
ROE N/A
ROIC N/A
ROA(3y)-46.91%
ROA(5y)-20.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CHRS Yearly ROA, ROE, ROICCHRS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1K 2K 3K

1.3 Margins

CHRS has a Gross Margin of 44.71%. This is in the better half of the industry: CHRS outperforms 77.44% of its industry peers.
In the last couple of years the Gross Margin of CHRS has declined.
The Profit Margin and Operating Margin are not available for CHRS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 44.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-25.43%
GM growth 5YN/A
CHRS Yearly Profit, Operating, Gross MarginsCHRS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5K -10K

More info and screens

2

2. Health

2.1 Basic Checks

CHRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CHRS has more shares outstanding
The number of shares outstanding for CHRS has been increased compared to 5 years ago.
CHRS has a better debt/assets ratio than last year.
CHRS Yearly Shares OutstandingCHRS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
CHRS Yearly Total Debt VS Total AssetsCHRS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -4.09, we must say that CHRS is in the distress zone and has some risk of bankruptcy.
CHRS has a Altman-Z score (-4.09) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.09
ROIC/WACCN/A
WACC8.32%
CHRS Yearly LT Debt VS Equity VS FCFCHRS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 1.25 indicates that CHRS should not have too much problems paying its short term obligations.
CHRS has a Current ratio of 1.25. This is amonst the worse of the industry: CHRS underperforms 84.55% of its industry peers.
CHRS has a Quick Ratio of 1.09. This is a normal value and indicates that CHRS is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of CHRS (1.09) is worse than 85.44% of its industry peers.
Industry RankSector Rank
Current Ratio 1.25
Quick Ratio 1.09
CHRS Yearly Current Assets VS Current LiabilitesCHRS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 45.50% over the past year.
CHRS shows a strong growth in Revenue. In the last year, the Revenue has grown by 44.17%.
CHRS shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -18.53% yearly.
EPS 1Y (TTM)45.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.3%
Revenue 1Y (TTM)44.17%
Revenue growth 3Y-18.53%
Revenue growth 5YN/A
Sales Q2Q%-5.09%

3.2 Future

Based on estimates for the next years, CHRS will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.13% on average per year.
Based on estimates for the next years, CHRS will show a small growth in Revenue. The Revenue will grow by 6.80% on average per year.
EPS Next Y56.68%
EPS Next 2Y33.24%
EPS Next 3Y22.48%
EPS Next 5Y17.13%
Revenue Next Year-1.89%
Revenue Next 2Y-9.05%
Revenue Next 3Y0.67%
Revenue Next 5Y6.8%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CHRS Yearly Revenue VS EstimatesCHRS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
CHRS Yearly EPS VS EstimatesCHRS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CHRS. In the last year negative earnings were reported.
Also next year CHRS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CHRS Price Earnings VS Forward Price EarningsCHRS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CHRS Per share dataCHRS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

CHRS's earnings are expected to grow with 22.48% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.24%
EPS Next 3Y22.48%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CHRS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COHERUS BIOSCIENCES INC

NASDAQ:CHRS (2/21/2025, 8:08:47 PM)

After market: 1.09 +0.02 (+1.87%)

1.07

-0.03 (-2.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)02-27 2025-02-27/amc
Inst Owners57.37%
Inst Owner Change-20.22%
Ins Owners1.23%
Ins Owner Change-0.26%
Market Cap123.27M
Analysts83.08
Price Target6.2 (479.44%)
Short Float %27.93%
Short Ratio6.21
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)72.66%
Min EPS beat(2)52.67%
Max EPS beat(2)92.65%
EPS beat(4)2
Avg EPS beat(4)-73.62%
Min EPS beat(4)-410.06%
Max EPS beat(4)92.65%
EPS beat(8)5
Avg EPS beat(8)-33.29%
EPS beat(12)7
Avg EPS beat(12)-32.89%
EPS beat(16)7
Avg EPS beat(16)-44.69%
Revenue beat(2)2
Avg Revenue beat(2)10.48%
Min Revenue beat(2)3.81%
Max Revenue beat(2)17.15%
Revenue beat(4)2
Avg Revenue beat(4)2.05%
Min Revenue beat(4)-6.92%
Max Revenue beat(4)17.15%
Revenue beat(8)3
Avg Revenue beat(8)-5.34%
Revenue beat(12)3
Avg Revenue beat(12)-8.32%
Revenue beat(16)3
Avg Revenue beat(16)-8.44%
PT rev (1m)-28.43%
PT rev (3m)-35.97%
EPS NQ rev (1m)-3.06%
EPS NQ rev (3m)-28.2%
EPS NY rev (1m)-0.19%
EPS NY rev (3m)3.38%
Revenue NQ rev (1m)7.23%
Revenue NQ rev (3m)-6.6%
Revenue NY rev (1m)-0.39%
Revenue NY rev (3m)-1.22%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.41
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.09
EYN/A
EPS(NY)-0.45
Fwd EYN/A
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)-0.54
OCFYN/A
SpS2.64
BVpS-0.76
TBVpS-1.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.09%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 44.71%
FCFM N/A
ROA(3y)-46.91%
ROA(5y)-20.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-25.43%
GM growth 5YN/A
F-Score3
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.25
Quick Ratio 1.09
Altman-Z -4.09
F-Score3
WACC8.32%
ROIC/WACCN/A
Cap/Depr(3y)32.91%
Cap/Depr(5y)80.31%
Cap/Sales(3y)0.49%
Cap/Sales(5y)0.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.3%
EPS Next Y56.68%
EPS Next 2Y33.24%
EPS Next 3Y22.48%
EPS Next 5Y17.13%
Revenue 1Y (TTM)44.17%
Revenue growth 3Y-18.53%
Revenue growth 5YN/A
Sales Q2Q%-5.09%
Revenue Next Year-1.89%
Revenue Next 2Y-9.05%
Revenue Next 3Y0.67%
Revenue Next 5Y6.8%
EBIT growth 1Y29.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.03%
EBIT Next 3Y27.29%
EBIT Next 5Y18.1%
FCF growth 1Y68.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y67.94%
OCF growth 3YN/A
OCF growth 5YN/A